Posts in category Analyst News


Roth Capital Maintains Buy on First Solar, Inc. (FSLR) as ITC Vote Backs Suniva Injury Claims

201 injury found – What does it mean for First Solar?

Read more

Canaccord Highlights Upcoming Catalysts For Palatin Technologies, Inc. (PTN) Bulls

John Newman continues to expect NDA in 2018 for bremelanotide, while pipeline moves forward.

Read more

Valeant Pharmaceuticals Intl Inc (VRX): Analyst Louise Chen Provides Key Takeaways Following a Fireside Chat with CFO

CFO Paul Herendeen sought out to convince investors to put their money into the long game.

Read more

Here’s Why H.C. Wainwright Just Cut the Price Target for Synergy Pharmaceuticals Inc (SGYP) by 50%

Ram Selvaraju slashes his target to $8 on slower Trulance ramp.

Read more

Canaccord Slashes Price Target for Versartis Inc to $9.00 as GHD Drug Flunks Phase 3 Trial

Could Versartis recover after today’s big decline?

Read more

Nokia Oyj (ADR) (NOK): Here’s Why This Top Analyst Maintains a Cautious Stance

Michael Walkley revisits Nokia from the sidelines following LG patent ruling.

Read more

Maxim: Apple Inc. (AAPL) to Post Well Above Consensus EPS Results, Nutanix Inc (NTNX) Is Addressing a $22B Operating Profit Opportunity

Just before the weekend hits, Maxim’s Nehal Chokshi shares thoughts on his top tech picks: AAPL and NTNX.

Read more

Kenneth Herbert Shares Two Cents on Kratos Defense & Security Solutions, Inc (KTOS) Following Investor Meetings with Management

A glimpse into recent investor meetings with management of Kratos Defense & Security.

Read more

Ask Analysts: Where Versartis Inc (VSAR), Ascendis Pharma A/S (ASND) Stocks Are Heading from Here?

A ‘game over’ for Versartis’ somavaratan; A powerful boost for Ascendis’ TC-hGH.

Read more

Top Analyst Cuts Price Target For Intercept Pharmaceuticals Inc (ICPT) By 50%; Here’s Why

Intercept Sank 40% in September following Dear Doctor and FDA warning letters; Ritu Baral weighs in.

Read more